5-Ht1 Agonists (Includes Amerge) ↔ Cad Risk Factors

The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease. As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur. Periodic cardiovascular evaluations should be performed during intermittent, long-term use.

5-Ht1 Agonists (Includes Amerge) ↔ Cardiovascular Disease

The use of 5-hydroxytryptamine1 receptor (5-HT1) agonists is contraindicated in patients with a current or past history of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases. In addition, these agents should not be used in patients with significant underlying cardiovascular diseases or uncontrolled hypertension. 5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities. However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.

Naratriptan (Includes Amerge) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

The manufacturer considers the use of naratriptan to be contraindicated in patients with severe hepatic impairment (Child-Pugh grade C). Naratriptan is partially metabolized by the liver. In patients with moderate hepatic impairment (Child-Pugh grade A or B), the clearance of naratriptan has been shown to decrease by 30% compared to healthy controls, resulting in an approximately 40% increase in the mean half-life. A lower initial dosage should be considered in patients with mild or moderate hepatic impairment, and the maximum dosage should not exceed 2.5 mg per 24-hour period. There are no data concerning the use of naratriptan in patients with severe hepatic impairment, thus it is not recommended.

References

Naratriptan (Includes Amerge) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

The manufacturer considers the use of naratriptan to be contraindicated in patients with severe renal impairment (CrCl < 15 mL/min). Naratriptan is primarily eliminated by the kidney, approximately 50% as parent drug and 30% as metabolites. In patients with moderate renal impairment (CrCl = 18 to 39 mL/min), the clearance of naratriptan has been shown to decrease by 50% compared to healthy controls, resulting in an approximately 83% increase in the mean half-life. A lower initial dosage should be considered in patients with mild or moderate renal impairment, and the maximum dosage should not exceed 2.5 mg per 24-hour period. There are no data concerning the use of naratriptan in patients with severe renal impairment, thus it is not recommended.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

How to Prevent Deadly Drug Interactions

Some mixtures of medications can lead to serious and even fatal consequences.